In this commentary, I share my thoughts on the impact of recent data on treatment planning in early breast cancer, including how to incorporate PARP inhibition, CDK4/6 inhibition, and immunotherapy, along with the dilemmas and challenges surrounding their use.
This module offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.
This module offers an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.
In this module, an expert reviews germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.
This slideset offers an overview of current risk assessment and biomarker testing used to inform treatment decisions and predict treatment response and prognosis in patients with HER2-negative early breast cancer.
This slideset accompanies an expert analysis of the role of Ki-67 in risk assessment and discusses recently approved adjuvant abemaciclib for patients with HR-positive, HER2-negative EBC at high risk of recurrence.
Downloadable slideset describing germline BRCA mutations, biomarker testing, and adjuvant olaparib in the management of patients with gBRCA1/2-mutated, HER2-negative, high-risk early breast cancer.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.